Source-grounded facts extracted from Sana Biotechnology, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sana Biotechnology, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“Proposal 2: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, by the votes set forth in the table below:”
Sana Biotechnology, Inc. shareholders approved Election of Class II directors for a three-year term expiring at the 2029 annual meeting at the 2026-06-04 meeting.
“Proposal 1: The Company’s stockholders elected all the nominees to serve as Class II directors of the Company’s Board of Directors, each to serve for a three-year term expiring at the Company’s 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified, by the votes set forth in the table below:”
Sana Biotechnology, Inc. reported financial results for first quarter 2026.
“On May 11, 2026, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.”
Susan Wyrick was appointed as Acting Chief Financial Officer, Treasurer, and Principal Accounting Officer at Sana Biotechnology, Inc..
“Susan Wyrick, the Company’s Senior Vice President, Finance and Accounting, was appointed to serve as Acting Chief Financial Officer, Treasurer, and PAO”
Steven D. Harr was appointed as acting Principal Financial Officer at Sana Biotechnology, Inc..
“Steven D. Harr, M.D., the Company’s President and Chief Executive Officer, was appointed to serve as acting PFO in addition to his role as President and Chief Executive Officer.”
Nathan Hardy resigned as Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer at Sana Biotechnology, Inc..
“Nathan Hardy’s resignation as Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer (“PFO”), and Principal Accounting Officer (“PAO”)”
Nathan Hardy resigned as Executive Vice President and Chief Financial Officer at Sana Biotechnology, Inc..
“On September 6, 2024, Nathan Hardy notified Sana Biotechnology, Inc. (the “Company”) that he intends to resign from his position as Executive Vice President and Chief Financial Officer of the Company effective October 4, 2024.”
Sana Biotechnology, Inc. reported financial results for the quarter and year ended March 31, 2024.
“On May 8, 2024, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended March 31, 2024.”
Douglas Williams resigned as Executive Vice President and President, Research and Development at Sana Biotechnology, Inc..
“Effective April 18, 2024, Douglas Williams, Ph.D. resigned from his position as Executive Vice President and President, Research and Development of Sana Biotechnology, Inc. (the “Company”).”
Sana Biotechnology, Inc. reported financial results for the quarter and year ended December 31, 2023.
“On February 29, 2024, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.”
Sana Biotechnology, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and BofA Securities, Inc., as representatives valued at approximately $156.6 million (effective 2024-02-07).
“On February 7, 2024, Sana Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and BofA Securities, Inc., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 17,272,728 shares of the Company’s common stock, par value $0.0001 per share, at a price to the public of $5.50 per share (the “Underwritten Shares”), and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 12,727,272 shares of the Company’s common stock at a price to the public of $5.4999 per underlying share.”
Sana Biotechnology, Inc. reported financial results for third quarter 2023.
“On November 8, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.”
Sana Biotechnology, Inc. announced a restructuring with charges of approximately $5.1 million and $1.7 million affecting fusogen platform for in vivo gene delivery (approximately 29%).
“On October 10, 2023, Sana Biotechnology, Inc. (“Sana”) announced a portfolio update to increase its focus on its ex vivo cell therapy product candidates. As part of the portfolio update, Sana plans to reduce its near-term investment in its fusogen platform for in vivo gene delivery, including by delaying the investigational new drug (IND) filing for its SG299 program, and reduce its workforce by approximately 29%. Sana anticipates that the portfolio update and associated reduction in force will be substantially complete by the fourth quarter of 2023, which is expected to result in 2024 operating cash burn of less than $200.0 million. In connection with the portfolio update, Sana anticipates it will incur approximately $5.1 million and $1.7 million of cash-based expenses related to employee severance, benefits and related costs in the fourth quarter of 2023 and the first quarter of 2024, respectively.”
Sana Biotechnology, Inc. terminated Lease Agreement with Pacific Commons Owner, LP valued at termination fee of approximately $3.42 million (effective 2023-08-30).
“On August 17, 2023, Sana Biotechnology, Inc. (the “ Company ”) entered into a Lease Termination Agreement (the “ Termination Agreement ”) with Pacific Commons Owner, LP (the “ Landlord ”) for the early termination of that certain Lease Agreement between the Company and the Landlord dated July 13, 2021 (the “ Lease ”), pursuant to which the Company leased 163,193 square feet of industrial space located at 5567 Cushing Parkway in Fremont, California (the “ Fremont Premises ”). Under the Termination Agreement, the Lease will terminate on August 30, 2023, and the Company will surrender its rights to the Fremont Premises on or before such date. The Company will pay the Landlord a termination fee of approximately $3.42 million, and the Landlord will return to the Company the irrevocable letter of credit provided by the Company as security under the Lease.”
Sana Biotechnology, Inc. reported financial results for the quarter and year ended June 30, 2023.
“On August 3, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended June 30, 2023.”
Sana Biotechnology, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-08 meeting.
“Proposal 2: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, by the votes set forth in the table below: For Against Abstain 142,770,600 184,749 125,243”
Sana Biotechnology, Inc. shareholders approved Election of three Class II directors to serve until 2026 at the 2023-06-08 meeting.
“Proposal 1: The Company’s stockholders elected all the nominees to serve as Class II directors of the Company’s Board of Directors, each to serve for a three-year term expiring at the Company’s 2026 annual meeting of stockholders or until his or her respective successor is duly elected and qualified, by the votes set forth in the table below: Nominees For Withheld Broker Non-Votes Hans E. Bishop 108,928,064 19,856,165 14,296,363 Robert Nelsen 111,403,976 17,380,253 14,296,363 Alise S. Reicin, M.D. 110,664,981 18,119,248 14,296,363”
Sana Biotechnology, Inc. reported financial results for the quarter and year ended March 31, 2023.
“On May 8, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended March 31, 2023.”
Sunil Agarwal resigned as Executive Vice President, Head of Development, and Chief Medical Officer at Sana Biotechnology, Inc..
“Sana Biotechnology, Inc. (the “Company”) previously filed a Current Report on Form 8-K disclosing the resignation of Sunil Agarwal, M.D. as the Company’s Executive Vice President, Head of Development, and Chief Medical Officer.”
Sunil Agarwal resigned as Executive Vice President, Head of Development, and Chief Medical Officer at Sana Biotechnology, Inc..
“Sunil Agarwal, M.D. resigned from his position as Executive Vice President, Head of Development, and Chief Medical Officer of the Company, effective as of April 10, 2023.”
Douglas E. Williams was appointed as Executive Vice President and President, Research and Development at Sana Biotechnology, Inc..
“Douglas E. Williams, Ph.D., has been appointed and will join the Company as Executive Vice President and President, Research and Development, effective April 10, 2023.”
Sana Biotechnology, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
“On March 16, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.”
Sana Biotechnology, Inc. announced a restructuring with charges of approximately $7.9 million of cash-based expenses related to employee severance, benefits and related costs; and approximately $2.2 million non-cash stock-based (approximately 15%).
“On November 29, 2022, Sana Biotechnology, Inc. (“Sana”) issued a press release announcing a portfolio prioritization and corporate restructuring designed to optimize development of its programs at or nearing clinical development, to continue investments in its core research platforms and innovation, and to maintain a strong balance sheet with an expected cash runway into 2025. As part of the prioritization and restructuring, Sana will reduce its workforce by approximately 15% by the end of 2022. In connection with the restructuring, Sana anticipates it will incur approximately $7.9 million of cash-based expenses related to employee severance, benefits and related costs, primarily in the fourth quarter of 2022, when it anticipates that the restructuring will be substantially complete. In addition, Sana expects to record a non-cash stock-based compensation charge of approximately $2.2 million related to modification of equity awards for employees impacted by the restructuring.”
Sana Biotechnology, Inc. reported financial results for the quarter and year ended September 30, 2022.
“On November 2, 2022, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended September 30, 2022.”
Sana Biotechnology, Inc.: 董事会通过了经修订和重述的商业行为和道德准则，包括有关潜在利益冲突的额外讨论。 (effective 2022-10-27).
“On October 27, 2022, the Board of Directors (the “ Board ”) of Sana Biotechnology, Inc. (the “ Company ”) adopted the Company’s amended and restated Code of Business Conduct and Ethics (the “ Revised Code of Conduct ”).”
Geoffrey von Maltzahn resigned as Director at Sana Biotechnology, Inc..
“On September 1, 2021, Geoffrey von Maltzahn, Ph.D. notified Sana Biotechnology, Inc. (“Sana”) of his decision to resign from the Board of Directors of Sana (the “Board”), effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.